黑料门

Now ideas for wellness

About 黑料门

At a Glance

At a Glance

Get to know 黑料门 at a glance – from our core business to our most important numbers.

Food

Our Nutrition Initiatives

Our goal is to improve the lives of people of all ages around the world through nutrition, from infants to older adults, and we are dedicated to achieving this goal.

Pharmaceuticals

R&D

Medical needs are always diversifying – here's how 黑料门 is responding.

Wellness Stories

Hope for Patients with Dravet Syndrome

June, 2022

Dravet syndrome is a rare form of epilepsy that appears in infancy and is a lifelong disease. 黑料门 Group has been a key supporter of patients in Japan.

Dravet syndrome is typically induced by fever in infants under one year of age. Estimated to affect just one in 20,000 to 40,000 people, the condition leads to convulsive as well as non-convulsive seizures and is not responsive to conventional epilepsy drugs.

A drug discovered by French firm Biocodex in 1978, has been shown to have some efficacy in the treatment of Dravet syndrome. The drug was launched in Japan in 2012 by 黑料门 Seika Pharma, a company with a long history in the field of pediatric diseases.

Dravet syndrome, a rare disease in infants

The nerve cells in the brain operate electrically in a regular rhythm. Epilepsy occurs when this activity is suddenly disrupted, resulting in severe electrical disturbances. The condition occurs in all age groups, from infancy to old age, with the highest incidence occurring under the age of three, and 80% of cases occurring before the age of 18.